Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.

Ansari SH, Shamsi TS, Ashraf M, Perveen K, Farzana T, Bohray M, Erum S, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2011;33(5):339-43.

Indicizzato‎: PubMed 21602718

DOI‎: 10.1097/MPH.0b013e31821b0770

https://www.ncbi.nlm.nih.gov/pubmed/21602718

Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.

Ansari SH, Shamsi TS, Munzir S, Khan MT, Erum S, Perveen K, Farzana T, Ashraf M, Mehboob T, Moinuddin M.

Fonte‎: J Pediatr Hematol Oncol 2013;35(4):e153-6.

Indicizzato‎: PubMed 23389500

DOI‎: 10.1097/MPH.0b013e31827e8662

https://www.ncbi.nlm.nih.gov/pubmed/23389500

Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).

Ansari SH, Shamsi TS, Siddiqui FJ, Irfan M, Perveen K, Farzana T, Panjwani VK, Yousuf A, Mehboob T.

Fonte‎: J Pediatr Hematol Oncol 2007;29(11):743-6.

Indicizzato‎: PubMed 17984691

DOI‎: 10.1097/MPH.0b013e318157fd75

https://www.ncbi.nlm.nih.gov/pubmed/17984691

Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.

Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M.

Fonte‎: Blood 2003;102(4):1529-30.

Indicizzato‎: PubMed 12702505

DOI‎: 10.1182/blood-2003-01-0117

https://www.ncbi.nlm.nih.gov/pubmed/12702505

Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.

Bradai M, Pissard S, Abad MT, Dechartres A, Ribeil JA, Landais P, de Montalembert M.

Fonte‎: Transfusion 2007;47(10):1830-6.

Indicizzato‎: PubMed 17880608

DOI‎: 10.1111/j.1537-2995.2007.01399.x

https://www.ncbi.nlm.nih.gov/pubmed/17880608

Hydroxyurea can reduce or eliminate transfusion requirements in children with major and intermediate thalassemia.

Hashemi A, Abrishamkar M, Jenabzade AR, Eslami Z.

Fonte‎: Iran J Blood Cancer 2009;1(4):147-50.

Indicizzato‎: IMEMR 107228

https://www.ijbc.ir/browse.php?a_id=4&sid=1&slc_lang=en

Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.

Karimi M, Haghpanah S, Farhadi A, Yavarian M.

Fonte‎: Int J Hematol 2012;95(1):51-6.

Indicizzato‎: PubMed 22180324

DOI‎: 10.1007/s12185-011-0985-6

https://www.ncbi.nlm.nih.gov/pubmed/22180324

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.

Perrine SP.

Fonte‎: Pediatr Ann 2008;37(5):339-46.

Indicizzato‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545

Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC.

Fonte‎: Haematologica 2004;89(10):1172-8.

Indicizzato‎: PubMed 15477200

https://www.ncbi.nlm.nih.gov/pubmed/15477200

Hydroxyurea therapy in 49 patients with major beta-thalassemia.

Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A.

Fonte‎: Arch Iran Med 2009;12(3):295-7.

Indicizzato‎: PubMed 19400608

https://www.ncbi.nlm.nih.gov/pubmed/19400608

Use of hydroxyurea and recombinant erythropoietin in management of homozygous ß⁰ thalassemia.

Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.

Fonte‎: J Pediatr Hematol Oncol 2002;24(9):777-8.

Indicizzato‎: PubMed 12468925

https://www.ncbi.nlm.nih.gov/pubmed/12468925

Termination of transfusion dependence in beta-thalassemia: two-year experience with recombinant human erythropoietin.

Nişli G, Kavakli K, Aydinok Y, Oztop S, Cetingül N.

Fonte‎: Pediatr Hematol Oncol 1997;14(3):285-7.

Indicizzato‎: PubMed 9185215

https://www.ncbi.nlm.nih.gov/pubmed/9185215

Fetal globin gene inducers: novel agents and new potential.

Perrine SP, Castaneda SA, Chui DH, Faller DV, Berenson RJ, Siritanaratku N, Fucharoen S.

Fonte‎: Ann N Y Acad Sci 2010;1202:158-64.

Indicizzato‎: PubMed 20712788

DOI‎: 10.1111/j.1749-6632.2010.05593.x

https://www.ncbi.nlm.nih.gov/pubmed/20712788